ã¡ãã£ã¢èšäº
ãã³ããæ²»çè¬ãšããŠããœããããããæ¿èªãååŽçã«ç³è«
ããºãææ°ããŒã¯ 354
twitterã³ã¡ã³ã 170ä»¶äž 1ïœ100件
èªã¿é£ãååã ãã
èãåã¿ããã ã
æ©ããç¹å¹è¬åºæ¥ãªãããã
èãåã¿ããã ã
æ©ããç¹å¹è¬åºæ¥ãªãããã
ã¡ãªã¿ã«ãããããè«äºã¯ãåªç§ãªæ²»çè¬ãã§ãŠããã°çµããã«ãªããšæããŸã
å¡©é矩ã®ã«ã¯ãã«çæ³ããããŸãããæè¿ããããèªå¯ãããŸãã
è¬ã足ããªããšããç¶æ³ã解æ¶ãããã°ãã³ããéšãã¯çµããã§ããããããããŸããªãã ãšæããŸã
å¡©é矩ã®ã«ã¯ãã«çæ³ããããŸãããæè¿ããããèªå¯ãããŸãã
è¬ã足ããªããšããç¶æ³ã解æ¶ãããã°ãã³ããéšãã¯çµããã§ããããããããŸããªãã ãšæããŸã
æ©æã«æ¿èªã§ãã®ã§ã¯ïŒ
ãã«ã¿æ ªãã©ã ãæ ªãªã©ã®å€ç°æ ªã«å¯ŸããŠã掻æ§ãç¶æãããšèããããååæäžã®ã¢ãã¯ããŒãã«æäœããœããããããã®æ¿èªç³è«ãšã®äºð€
察象ã¯ãé žçŽ çæ³ãå¿ èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è ããããã§ãã
察象ã¯ãé žçŽ çæ³ãå¿ èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è ããããã§ãã
ã»ã¢ãã¯ãããŒã«æäœ
ã»ç¹äŸæ¿èªã®é©çšãåžæ
ã»ãœãããããã¯ç¹æ»Žé泚ã§ãã³ããææçã§ã®é žçŽ çæ³ãå¿ èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è ãæäžå¯Ÿè±¡
GSKãã³ããæ²»çè¬ãšããŠããœããããããæ¿èªãååŽçã«ç³è«
2021.9.6
ã°ã©ã¯ãœ
ã»ç¹äŸæ¿èªã®é©çšãåžæ
ã»ãœãããããã¯ç¹æ»Žé泚ã§ãã³ããææçã§ã®é žçŽ çæ³ãå¿ èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è ãæäžå¯Ÿè±¡
GSKãã³ããæ²»çè¬ãšããŠããœããããããæ¿èªãååŽçã«ç³è«
2021.9.6
ã°ã©ã¯ãœ
æ²»çè¬ãåºæ¥ãã°æ®ããã®äžå®ã¯è§£æ¶ãããð
ç©ãããªæ¥åžžã«ãªããŸãããã«
å¯äœçšããäºãæ³å®å ã ãã©
ç©ãããªæ¥åžžã«ãªããŸãããã«
å¯äœçšããäºãæ³å®å ã ãã©
ã€ã³ãã«ãšã³ã¶ã10代20代30代ã®è¥è
ã§ã幎éæ°å人æ»è
åºãŠããã©ãã¯ã¯ãã³ãªããŠç¥ã£ããã£ã¡ããªã粟ç¥ã§éãããŠãã®ã¯æ²»çè¬ããã£ãããã§ãã
çµå±äººé¡ã欲ããã®ã¯ã¯ã¯ãã³ãããªããŠæ²»çè¬
çµå±äººé¡ã欲ããã®ã¯ã¯ã¯ãã³ãããªããŠæ²»çè¬
ãã¯ã¯ãã³ã®æ¬¡ã¯æäœã«ã¯ãã«ãïŒãâ¡
æäœè£œå€ã¯ããããããšããååãä»ããŠããã
åäžã®æäœç£ç现èãè€è£œããŠäœãããæäœãã¢ãã¯ããŒãã«æäœãšèšãã
è€æ°ã®æäœè£œå€ãæ··åããç©ãæäœã«ã¯ãã«ãšèšãã
å€éšããçŽæ¥æäœãç¹æ»Žã§äœå ã«å ¥ããäºã¯åãã§ããã
æäœè£œå€ã¯ããããããšããååãä»ããŠããã
åäžã®æäœç£ç现èãè€è£œããŠäœãããæäœãã¢ãã¯ããŒãã«æäœãšèšãã
è€æ°ã®æäœè£œå€ãæ··åããç©ãæäœã«ã¯ãã«ãšèšãã
å€éšããçŽæ¥æäœãç¹æ»Žã§äœå ã«å ¥ããäºã¯åãã§ããã
ãé
žçŽ çæ³ãå¿
èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è
ãæäžå¯Ÿè±¡ãšããŠããã
å®å šãªè¬ã ã£ãããã€ãªã¹ã¯æ£è ã§ãªããŠãæäžããŠããã ããã«
çãå®å šãªè¬ã䜿ããæ¥ã¯é ããªâŠâŠ
å®å šãªè¬ã ã£ãããã€ãªã¹ã¯æ£è ã§ãªããŠãæäžããŠããã ããã«
çãå®å šãªè¬ã䜿ããæ¥ã¯é ããªâŠâŠ
@ â» xâ»@ ããŒæ¥æ¬ã ãšé¢šéªè¬ã®ã³ã³ã¿ãã¯ã®ãšãããªãããã£ãŠã€ããŠãããã¢ãã¯ããŒãã«æäœããåé¡ã¯å¯äœçšã ãããã©ã
Reutersâ
ãã³ããæ²»çè¬ãšã㊠æ¿èªãååŽçã«ç³è«
ããã¯æå ±ã ãªãèšåºè©Šéšã§ã¯ã©ã®çšåºŠã®å¹æããã£ãã®ãã詳ããç¥ãããããã ç¹æ»ŽãšããåŠæ¹ã«é£ãããããé å€ãªã©ãžãšé²åããŠæ¬²ããã
ããã¯æå ±ã ãªãèšåºè©Šéšã§ã¯ã©ã®çšåºŠã®å¹æããã£ãã®ãã詳ããç¥ãããããã ç¹æ»ŽãšããåŠæ¹ã«é£ãããããé å€ãªã©ãžãšé²åããŠæ¬²ããã
ç¹æ»Žæ²»çåºæ¥ãããã«ãªãã®ã¯ããã§ãã
次ã®ããå€ãæ¥æ¬ã§äœ¿ããã®ã¯ã©ããããå
ã ããïŒ
ã¯ã¯ ãã³ããæ²»çè¬ã®æ¹ããããããã
ãŸãæäžã«å
¥ã£ãŠããããããªãçºé³ãã¥ããå称ã®ãåºãŠãããªâŠã
ãã¡ããæ²»çè¬ã®ç»å Žã¯æè¿ãªãã ãã©ãããã«èªãããšãèãã¡ãããªã
ãã¡ããæ²»çè¬ã®ç»å Žã¯æè¿ãªãã ãã©ãããã«èªãããšãèãã¡ãããªã
ãã¯ããããããŸãâ
GSKãæ°åã³ããæ²»çè¬ç³è«ãç¹äŸæ¿èªãåžæã
ãããããã®
mabïœmonoclonal antibodyãã®ãããŒãªãæäœ
ç¹æ»Žåæäœè¬
ãç¹äŸæ¿èªãç³è«
æäœç¹æ»Žè¬ãè±ã°ã©ã¯ãœãæ¿èªç³è«: èªå£²æ°èãªã³ã©ã€ã³
mabïœmonoclonal antibodyãã®ãããŒãªãæäœ
ç¹æ»Žåæäœè¬
ãç¹äŸæ¿èªãç³è«
æäœç¹æ»Žè¬ãè±ã°ã©ã¯ãœãæ¿èªç³è«: èªå£²æ°èãªã³ã©ã€ã³
9æ6æ¥ã®èšäºã§ãã
>ãœãããããã¯ç¹æ»Žé泚ã§ãã³ããææçã§ã®é
žçŽ çæ³ãå¿
èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è
ãæäžå¯Ÿè±¡ãšããŠãã
ãç¹æ»Žé泚ã§ãã³ããææçã§ã®é
žçŽ çæ³ãå¿
èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è
ãæäžå¯Ÿè±¡ãã ãã©å
¥é¢ããªããŠãç¹æ»Žã§ãããšããããïŒ
ãœããããã調ã¹ãããããªãéºäŒåçµã¿æãã£ãŠðŠ
ãã£ã€ããŒãºãã ã¹ã¿ãŒåµå·£çŽ°èã«ããç£çããããšâïžãªãã§ãã£ã€ããŒãºãã€ãâïžäœãç¹å¥ãªåçš®ãªã®ã ãããâïžãªããèããªã
ãã£ã€ããŒãºãã ã¹ã¿ãŒåµå·£çŽ°èã«ããç£çããããšâïžãªãã§ãã£ã€ããŒãºãã€ãâïžäœãç¹å¥ãªåçš®ãªã®ã ãããâïžãªããèããªã
ç¹äŸæ¿èª
ãœãããããã¯ç¹æ»Žé泚ã§ãé
žçŽ çæ³ãå¿
èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è
ãæäžå¯Ÿè±¡ã
欧å·é£åã¯7ææ«ãæ°åã³ããææçæ²»çè¬ãšããŠããœãããããã®äŸçµŠå¥çŽãç· çµïŒ
欧å·é£åã¯7ææ«ãæ°åã³ããææçæ²»çè¬ãšããŠããœãããããã®äŸçµŠå¥çŽãç· çµïŒ
æ²»çè¬âŠ
ããŠãã³ããçŠã®æäžäž»ã«ãªãã®ãâïž
ãããã©ã£ããšå䜵ããäŒç€Ÿã ã£ãããã確ãã
ãåœå
5äŸç®ãGSKãã³ããæ²»çè¬ãšããŠããœããããããæ¿èªãååŽçã«ç³è«
ã³ããæ²»çè¬ãšããŠãœãããããã®ç¹äŸæ¿èªãç³è«ããŠãŸãïŒ
ãŸãæ°ããã³ããæ²»çè¬ãç³è«ããããšãð€
å©æš©ã®äºå¥ªæŠã«ããèŠããªãã®ã§ããð
ã¯ã¯ãã³æ¥çš®âãœãããããæäžâå®æ²»âïžð€ð©
è¶çªã§ããð°
äœããããã®ã§ããããâïžð€
å©æš©ã®äºå¥ªæŠã«ããèŠããªãã®ã§ããð
ã¯ã¯ãã³æ¥çš®âãœãããããæäžâå®æ²»âïžð€ð©
è¶çªã§ããð°
äœããããã®ã§ããããâïžð€
ã³ããã®ãããªæ°èææçã§ãŠã€ã«ã¹ãã®ãã®ãã¿ãŒã²ããã«ããæãŠã€ã«ã¹è¬ã£ãŠå€ç°ã«å¯Ÿããæå¹æ§ã¯ã©ããªã®ãã
ããããããããããæ°èææçã®å Žåã¯æäœè¬ã®å¹æãé«ãããã«æãã
ããããããããããæ°èææçã®å Žåã¯æäœè¬ã®å¹æãé«ãããã«æãã
ãæ°åã³ãããŠã€ã«ã¹ã¯ãã ã®é¢šéªãäžæŽŸããŸãããããã®æ²»çè¬ã¯çæ¯ã ãã䜿çšãããïŒå¹Žä»¥å
ã«å
šå¡æ»ã¬ãã人å£åæžã®ããã®æ²»çè¬ããšèšãã ãããã
æåŸ
ããŠè¯ãã®ããªïŒ
Uã»Ïã»U
Uã»Ïã»U
å»åŠã®é²åãæããŸããå€ãã®æ²»éšããããšæããŸãããå®å
šã«æ©ææ²»çã«äœ¿ãããšã³ããåŸã®ç掻ãèŠãããã§ãã
è¬ã¯ãã£ãæ¹ãããã®ã ããã©ããäžè¬äººã«åããŠç¹å¹è¬ã®ããã«å ±éããã®ã¯ãããæ¹ãããã
趣æšãšã¯ãºã¬ããã©ãã³ããæ²»çè¬ãæäœçæ³ãšã€ãã«ã¡ã¯ãã³ã®2掟ã«åãããŠå®ææŠäºããŠãã®äœã§ã ããã
çŽæ¥ã®æ»å ã§ããå ç«æŽèµ°ãæããè¬ãæå¹ãšããçµæããå°ãªããšã什å2幎6æã«ã¯åºãŠãã®ã«ã
çŽæ¥ã®æ»å ã§ããå ç«æŽèµ°ãæããè¬ãæå¹ãšããçµæããå°ãªããšã什å2幎6æã«ã¯åºãŠãã®ã«ã
ååæšçæ²»çè¬ã£ãœãååã ãã©ã¢ãã¯ããŒãã«æäœãªã®ã
ç¹äŸæ¿èªãæ±ããŠãã
ããããã³ãããŠã€ã«ã¹ã®ååšã蚌æãããããŠã€ã«ã¹ã¯ç¡ããšå€å®ãããŠããã®ã«
æ²»çè¬ãšã¯ïŒ
äœåŠãŸã§ã人å£åæžãæ¢ããæ°ã¯ç¡ãæš¡æ§ð¿ð€¬ð
ããããã³ãããŠã€ã«ã¹ã®ååšã蚌æãããããŠã€ã«ã¹ã¯ç¡ããšå€å®ãããŠããã®ã«
æ²»çè¬ãšã¯ïŒ
äœåŠãŸã§ã人å£åæžãæ¢ããæ°ã¯ç¡ãæš¡æ§ð¿ð€¬ð
ããã¯é£²ã¿è¬ïŒç¹æ»ŽïŒçµå±é¢šéªè¬ã¿ãããªé£²ã¿è¬ãåºãªããšããã¯çµãããªããæ©ããŠå¹Žæããã
ããæ²»çè¬ãïŒãããŒã人é¡
æ¿èªåŸ
ã£ãŠãŸãã
ç¹æ»Žé泚ã®æ²»çè¬ã
ã²ãŒã ãã§ã³ãžã£ãŒã«ãªãããšãæåŸ
GlaxoSmithKline plcãæ²»çè¬ãåºãŠãããïŒæ¬¡ã¯Boehringer Ingelheim GmbHãããããåºãŠãããã§æåŸ
ã§ããã°ãããªã ïŒ
ãã€ã¿ãŒ
Evoããæ¥ãæ¥ãâŒïž
ããã«å¡©é矩補è¬ã®è¬ãç¶ãã°å ãèŠããð¶
ããã«å¡©é矩補è¬ã®è¬ãç¶ãã°å ãèŠããð¶
æ¬åœã«æ©ãæ²»çè¬ãã§ããŠã»ããïŒ
ãªã«ããïŒ
ãã¡ã€ã¶ãŒäºçŽãããã©ãããã£ã¡ãæã¡ãããã ãã©
ãã¡ã€ã¶ãŒäºçŽãããã©ãããã£ã¡ãæã¡ãããã ãã©
è¯ããã¥ãŒã¹âšæåŸ
ããŠãŸãð
æ¥æ¬ã«ã¯æ¥å¹Žãšãã¯ååŒããŠãðµðŠ
æ¥æ¬ã«ã¯æ¥å¹Žãšãã¯ååŒããŠãðµðŠ
>ãœãããããã¯ç¹æ»Žé泚ã§ãã³ãã
>ææçã§ã®é žçŽ çæ³ãå¿ èŠãšããªã
>軜çã»äžççãã€éçåãªã¹ã¯ãé«
>ããšèããããæ£è ãæäžå¯Ÿè±¡ãšã
>ãŠããã
軜ççšã®æ²»çè¬ãå¢ããã®ã¯æé£ããã©ç¹æ»Žã...å®äŸ¡ãªçµå£è¬åºæ¥ãªããã®ããªãã
>ææçã§ã®é žçŽ çæ³ãå¿ èŠãšããªã
>軜çã»äžççãã€éçåãªã¹ã¯ãé«
>ããšèããããæ£è ãæäžå¯Ÿè±¡ãšã
>ãŠããã
軜ççšã®æ²»çè¬ãå¢ããã®ã¯æé£ããã©ç¹æ»Žã...å®äŸ¡ãªçµå£è¬åºæ¥ãªããã®ããªãã
ã³ããæ²»çè¬ãšããŠããœããããããã®æ¿èªç³è«ãå§ãŸã£ãã
å€ç°æ ªã«ããã£ããäœçšãããããã
å€ç°æ ªã«ããã£ããäœçšãããããã
ã°ã©ã¯ãœã»ã¹ãã¹ã¯ã©ã€ã³(GSK)ã¯9/6ãã¢ãã¯ããŒãã«æäœã»ãœãããããã«ã€ããŠãæ°åã³ãããŠã€ã«ã¹ææçã®æ²»çè¬ãšããŠåçåŽåçã«è£œé 販売æ¿èªç³è«ãè¡ã£ããšçºè¡šããã欧å·é£åã¯7ææ«ãæ°åã³ãããŠã€ã«ã¹ææçæ²»çè¬ãšããŠããœãããããã®äŸçµŠå¥çŽãç· çµããŠããã
ç¹æ»Žããã§ã ããå®å¿ã ãšæãããçµå£æ²»çè¬ãæ©ãã§ãããšãããç¹æ»Žã§ãå€æ¥ã§ã§ããã°ãããšæããã ã®çµå£æ²»çè¬ãæ©ãã§ããã®ãç¥ã£ãŠã
ããããïŒ
æ ªãäžãã£ãŠããããšè¯ããâŠ
ãã¿ã€ãã³ã°ããããªãã
ã¯ã¯ãã³ã«ã±ããã€ãå§ããããããã«æ²»çè¬ãç³è«ã
æ©äŒãçã£ãŠããã§ãããããã
ã¯ã¯ãã³ã«ã±ããã€ãå§ããããããã«æ²»çè¬ãç³è«ã
æ©äŒãçã£ãŠããã§ãããããã
æ²»éšãæžãã§ãããªãã¯ã¯ãã³ã売ãæãããŸã§2é¡ä»¥äžãæ»å®ããæ¥æ¬æ¿åºãšå»åž«äŒãã³ããçŠã®æšå¹Žã¯ãããã1äžäººæžã£ãæ»äº¡è¶
éæ°ããã¯ã¯ãã³å°å
¥åŸã«3äžäººèŠæš¡ã«åã¶ã»ã©æ¿å¢ããŠããã®ãç¥ã£ãŠãã人ã¯ã©ããããããã®ã ãããã
ã¯ã¯ãã³ïŒæ²»çè¬ããäºæ
å®å®ã®éµãã¯ã¯ãã³ã®æ®åã®ããŒã¹ã§æ²»çè¬ãé²ãã§ããããšããã
åäžã®ã£ãŠèæ§ãåé¡ã«ãªã£ãŠ
äºçš®é¡ã®ã«ã¯ãã«ãªãOKãšãªãã®ã
å€ããã©ãè¡ããããªã®ããªã
äºçš®é¡ã®ã«ã¯ãã«ãªãOKãšãªãã®ã
å€ããã©ãè¡ããããªã®ããªã
ã¯ã¯ãã³æãããæ¹ãåœã«å©çã§ãã®ïŒ
ã¯ã¯ãã³ãçã«æãŠæãŠèšããã©ããã£ã¡ã®æ¹ãåãããããç¶æ³è¯ããªãããã ãã©ã
ã¯ã¯ãã³ãçã«æãŠæãŠèšããã©ããã£ã¡ã®æ¹ãåãããããç¶æ³è¯ããªãããã ãã©ã
æ²»çè¬ãå¢ããããšã¯ãããã ãå埩ã§ããæ段ãå¢ããããšã£ãŠãããããšã
ãŸãæäœæ³šå°ãã
ã¢ãã¬ã³ãã€ãã«ã¡ã¯ãã³ã®ãããªå æè¬ã¯æ¥æ¬ã®å°å£²ç¹èš±ãããã
ã¢ãã¬ã³ãã€ãã«ã¡ã¯ãã³ã®ãããªå æè¬ã¯æ¥æ¬ã®å°å£²ç¹èš±ãããã
ããã£ãèŠæ¹ãããã°ãè¬åŠéšã補è¬æ¥çã¯äººäœå®éšãæŸé¡ã®æ代ã ããªãã§ããèšå€§ãªæ²»éšããŒã¿ã«ãã£ãŠãä»ãŸã§ç¡ãã£ãããã©ãªã¢ã¯ã¯ãã³ãçã¯ã¯ãã³ãåºæ¥ãããïŒã
å³æ¿èªãªã飲ãã¹ããã
泚å°ãªãã§ãã(çœç®)
ãè¬é£²ãã®ãèŠæãªãåãããšãã«ã¯è¯ãããâŠç§ããã
ãè¬é£²ãã®ãèŠæãªãåãããšãã«ã¯è¯ãããâŠç§ããã
æ¥æ¬ã«ã¯ãã€æ¥ããã ããïŒ
åžæã®å
ãªã®ãâŠâš
æ©ãå®çŸã§ããäºãé¡ããŸãðâš
æ©ãå®çŸã§ããäºãé¡ããŸãðâš
ããããåžæã®å
ãšãªããïŒ
è¯ãå æžãåœç£æ²»çè¬ãã¯ã¯ãã³ãæ¿èªãã¹ãã
ã¯ã¯ãã³ã§ã¯å®å
šã«äºé²ã§ããªãããæ©ãè²ããªæ²»çè¬ãã§ããŠã³ããåã®ç掻ã«æ»ãããšãããªããŒ
ããã£ïŒ
ïŒã³ããææçã§ã®é
žçŽ çæ³ãå¿
èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è
ãæäžå¯Ÿè±¡
ïŒæ¬§å·é£åã¯ïŒææ«ãæ°åã³ãããŠã€ã«ã¹ææçæ²»çè¬ãšããŠããœãããããã®äŸçµŠå¥çŽãç· çµ
ïŒæ¬§å·é£åã¯ïŒææ«ãæ°åã³ãããŠã€ã«ã¹ææçæ²»çè¬ãšããŠããœãããããã®äŸçµŠå¥çŽãç· çµ
ã©ãã©ãè¯ãæ²»çè¬ãåºãŠããããšã«æåŸ
âïž
ã°ã©ã¯ãœã»ã¹ãã¹ã¯ã©ã€ã³ã¯6æ¥ãã¢ãã¯ããŒãã«æäœããœããããããã®è£œé 販売æ¿èªç³è«ãè¡ã£ããšçºè¡šãããæ°åã³ãããŠã€ã«ã¹ææçã®æ²»çè¬ãšããŠãåçåŽåçã«è£œé 販売æ¿èªç³è«ãè¡ã£ããç¹äŸæ¿èªã®é©çšãåžæããŠãããšã®ããšã
ãœãããããã¯ç¹æ»Žé泚ã§ãã³ããææçã§ã®é
žçŽ çæ³ãå¿
èŠãšããªã軜çã»äžççãã€éçåãªã¹ã¯ãé«ããšèããããæ£è
ãæäžå¯Ÿè±¡ã
ãœããšãã©ãïŒïŒÎ£(;ÂŽÐ`)
ã©ãã©ãæ²»çè¬ãåºãŠããŠãŸããð€
ãœãããããã
æ°ããè¬ãç³è«ãããã®ã¯è¯ãäºã ãã©
å»é¢ã§åŠæ¹ããŠããã£ãŠ
èªå® ã§å¯Ÿå¿åºæ¥ãçµå£è¬ãæ©ãåºãŠæ¬²ããã
å»é¢ã§åŠæ¹ããŠããã£ãŠ
èªå® ã§å¯Ÿå¿åºæ¥ãçµå£è¬ãæ©ãåºãŠæ¬²ããã
ãŸãæäœç³»ããè¬äŸ¡ãã€ããã
ãããïŒïŒïŒïŒïŒæ¥ããæ²»çè¬ïŒïŒ
ãŸã ãŸã æªç¥ã£ãšæããã©åžæã®å ã ïŒ
ãŸã ãŸã æªç¥ã£ãšæããã©åžæã®å ã ïŒ
ããïŒã€ãã«ïŒ
ãœããããããèåã¿ããð
ïŒ
â
â
ããã¯æåŸ
ã§ãããããªïŒ
ãšããŠã ã ã«
æµ·å€ã¯é 匵ã£ãŠããªããæ¥æ¬ã®ãããªåŸé²åœã¯ã¯ã¯ãã³ãæ²»çè¬ãéçºã§ãããå
é²åœãã賌å
¥ããã€ãŸã§ãã£ãŠããå¯åå¿ãæãïŒããå©æš©ã ïŒããšæå¥ã ãã¯äžäžåã«åãç¶ããã®ã§ãã
$GSK
æã£ãŠãªãâ
èŠããã§ãã人ããæ©ããæããããšã€ã€â
æã£ãŠãªãâ
èŠããã§ãã人ããæ©ããæããããšã€ã€â
æäœã«ã¯ãã«çæ³ãšãããªå€ããããããããã
éšããããªå€¢ã®è¬ãããªãã
ç¹æ»Žã ãå ¥é¢ããªããšäœ¿ããªããã
飲ã¿è¬ãã¯ãã§ããããªãã
ããããæ¿æ²»å®¶ããããç¡èœã§ãåé¡ãªããªãããã
éšããããªå€¢ã®è¬ãããªãã
ç¹æ»Žã ãå ¥é¢ããªããšäœ¿ããªããã
飲ã¿è¬ãã¯ãã§ããããªãã
ããããæ¿æ²»å®¶ããããç¡èœã§ãåé¡ãªããªãããã
è¬ããŒããè¬ããŒððð
(:.;ïŸ;Ð;ïŸ;.:)ïŸïœ§ïŸïœ§
(:.;ïŸ;Ð;ïŸ;.:)ïŸïœ§ïŸïœ§
ã¢ãã¬ã³å¹ããªãã®ããªãïŒ
ãã®ç¹æ§ãããããšæå¹ãããªãã ãã©ïœ¥ïœ¥ïœ¥
ãã®ç¹æ§ãããããšæå¹ãããªãã ãã©ïœ¥ïœ¥ïœ¥
å¯èœãªãåœç£ããããã©ãããã®æå¹æ§ãšãªã¹ã¯ãç
§ããåãããŠãæå¹ããšèªãããããããªã¹ã¯ããããããã¯ã¯ãã³æ¥çš®ã®å¿
èŠæ§ã1ã€æžããªã
人éãããã°ã£ãŠããããããð
è±ç±³å¢ãäœã£ãè¬ðãããã§ãããããŠã€ã«ã¹ãŸãããã§ããã
GSKãšç±³åµè¬ãã³ãã£ãŒã®ãã¢ã»ãã€ãªãã¯ãããžãŒãå ±åéçºã
GSKãšç±³åµè¬ãã³ãã£ãŒã®ãã¢ã»ãã€ãªãã¯ãããžãŒãå ±åéçºã
ããããæ²»çè¬ããããããããããã€ãå»ãã¬ãã«ã§äœ¿ããããã«ãªã£ãŠããã£ãšå
ãèŠããæãã
ã©ããªã¯ã¯ãã³ã ã£ãŠãææãé²ããã®ãããªããããããã£ãŠåœããåã
ã©ããªã¯ã¯ãã³ã ã£ãŠãææãé²ããã®ãããªããããããã£ãŠåœããåã
ã³ããæ²»çè¬ãååŽçã«ç³è«ãç¹äŸæ¿èªãåžæððŒ
EUãé¢è±ããã€ã®ãªã¹ã®æŽ»èºã倧ãããã
ç¹æ»ŽãâŠ
ãã®åœã¯å ¥é¢ããå°é£âŠ
ãã®åœã¯å ¥é¢ããå°é£âŠ
ããŒãããŸãç¹æ»Žè¬ããããªããšãæ©ãå£è
å€ãåºãªãããªãããããã°ãã»ããšã«å
ãèŠãããšæããã ãã
å㞠次ãž
察åŠè¬ãåºæ¥ãŠã家ççšã®ã€ãã«ã¡ã¯ãã³ïŒãªã®ããããïŒïŒ